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PHypertrophic Cardiomyopathy
ilated-Hypokinetic Evolution
f Hypertrophic Cardiomyopathy
revalence, Incidence, Risk Factors,
nd Prognostic Implications in Pediatric and Adult Patients
lena Biagini, MD,* Fabio Coccolo, MD,* Marinella Ferlito, MD,* Enrica Perugini, MD,*
uido Rocchi, MD,* Letizia Bacchi-Reggiani, BSC,* Carla Lofiego, MD,* Giuseppe Boriani, MD,*
aniela Prandstraller, MD,† Fernando M. Picchio, MD,† Angelo Branzi, MD,* Claudio Rapezzi, MD*
ologna, Italy
OBJECTIVES This study sought to investigate the incidence, risk factors, and prognosis of dilated-
hypokinetic evolution in a large cohort of patients with hypertrophic cardiomyopathy (HCM)
followed up at a cardiology center serving both the pediatric and the adult population.
BACKGROUND The available data on this evolution of HCM mainly regards prevalence (rather than
incidence) in adults, with very little being known about the pediatric population.
METHODS A total of 222 consecutive HCM patients (65% men, 19% 18 years old) were prospectively
evaluated for a mean follow-up of 11  9 years.
RESULTS A diagnosis of dilated-hypokinetic HCM was made in 12 patients at first evaluation (11
without previous septal myectomy surgery; prevalence, 4.9%). Twelve of the 210 patients with
classic HCM at first evaluation underwent dilated-hypokinetic evolution (incidence, 5.3/1,000
patient-years). Patients with prevalent/incident dilated-hypokinetic evolution were younger at first
evaluation (32  14 years vs. 41  21 years, p  0.04) and more often had a family history of
HCM (61% vs. 26%, p 0.002) or sudden death (43% vs. 19%, p 0.01) with respect to patients
who maintained classic HCM. Moreover, they showed greater interventricular septum (23  3
mm vs. 19  6 mm, p  0.004) and posterior wall (15  3 mm vs. 13  4 mm, p  0.006)
thickness. Cardiovascular death-free survival was lower among patients with dilated-
hypokinetic HCM (p  0.04). Cox proportional hazards regression analysis identified left
ventricular wall thickness (hazard ratio [HR]  1.07; 95% confidence interval [CI], 1.01 to
1.14; p  0.03) and end-diastolic diameter (HR  1.08; 95% CI 1.04 to 1.11; p  0.0001)
as independent predictors of cardiovascular death.
CONCLUSIONS Dilated-hypokinetic evolution is rare but not exceptional in HCM. Young age at diagnosis,
family history of HCM, and greater wall thickness are incremental risk factors for
dilated-hypokinetic HCM, which carries an ominous prognosis. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.06246:1543–50) © 2005 by the American College of Cardiology Foundation
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ave normal systolic function (in terms of left ventricular
jection fraction [LVEF] and other ejection indices) in the
ontext of impaired diastolic function and reduced left
entricular (LV) end-diastolic volume. However, in a mi-
ority of patients HCM evolves into a phase characterized
y systolic dysfunction, LV dilation, and wall thinning,
esembling the morphologic and functional features of
See page 1551
ilated cardiomyopathy (Fig. 1). This dilated-hypokinetic
volution of HCM is often designated as end-stage, burn-
ut phase (1–10), or progressive disease (11). This peculiar
isease pathway, which had already been clearly described in
From the *Institute of Cardiology and the †Pediatric Cardiology and Adult
ongenital Unit, University of Bologna, Bologna, Italy.c
Manuscript received February 3, 2005; revised manuscript received April 20, 2005,
ccepted April 25, 2005.he 1980s (1,2,4–7,9), has recently attracted renewed sci-
ntific interest for at least two reasons. On pathogenetic
rounds, it has recently been reported that mutations in
arcomere protein genes can cause either HCM or dilated
ardiomyopathy, stimulating two different pathobiological
vents that remodel the heart (12). Clinically, dilated-
ypokinetic evolution is one of the pathophysiologic sub-
trates for heart failure in patients with HCM, among
hom it is also the single most frequent indication for heart
ransplantation (3,13,14).
The available data on the occurrence of dilated-
ypokinetic evolution of HCM mainly regards prevalence
rather than incidence) of adult cases, with very little being
nown about the pediatric population (15,16). In the
resent study, we investigated the incidence, risk factors,
atural history, and prognostic implications of dilated-
ypokinetic evolution of HCM in a large population of
atients with HCM routinely followed up at a cardiology
enter serving both the pediatric and the adult population.
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ligibility criteria and recruitment. The population of
his observational study comprised 222 patients with a
iagnosis of HCM under observation between 1964 and
002 in the standard inpatient/outpatient clinics of our
ardiology center in a public teaching hospital open to a
arge local and regional population. In particular, the study
egarded all patients with either a de novo diagnosis of
CM made in our center or an existing diagnosis of HCM
ho were referred to us for follow-up purposes (all instru-
ental and clinical findings, including familial analysis with
edigree reconstruction, are routinely stored in an electronic
atabase). The single inclusion criterion was diagnosis of
CM based on two-dimensional echocardiographic evi-
ence of a nondilated and hypertrophic LV—defined as
all thickness of 15 mm in adults, or the equivalent with
espect to body surface area in children (16)—in the absence
f another cardiac or systemic disease that could produce a
Abbreviations and Acronyms
CI  confidence interval
HCM  hypertrophic cardiomyopathy
HR  hazard ratio
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
igure 1. A representative example of evolution to dilated-hypokinetic hyp
chocardiogram (at age 13 years) shows HCM with massive left ventricula
all, accompanied by diminutive LV cavity size. (B) Three years later (at age 16
he context of severe heart failure, requiring heart transplantation.imilar degree of hypertrophy (17). Exclusion criteria were
resence of Friedreich ataxia or Noonan syndrome (based
n careful clinical analysis of phenotype), Pompe disease
clinical and enzymatic evaluation), or mitochondrial disease
exclusion of multiorgan involvement, and in selected pa-
ients, histologic evaluation of skeletal muscle biopsy or
itochondrial DNA analysis). In patients evaluated before
chocardiography was introduced into our clinical practice
in 1984), the diagnosis of HCM was made by typical
lectrocardiographic features combined with angiographic
ndings (17) and was subsequently confirmed by echocar-
iography (18).
Those patients residing within easy distance to the clinic
ere regularly followed up in our outpatient clinic according
o our routine institutional program, comprising two
lanned clinical check ups and one echocardiographic ex-
mination per year. The remainder of the population (38
atients) was recalled (by mail and then telephone) for an
chocardiographic and clinical check up at the end of the
tudy period. Data regarding time and circumstances of
eath were obtained from relatives and physicians (consult-
ng clinical records and death certificates when necessary).
ll patients provided written informed consent to anony-
ous use of their data for research purposes. In line with
ational and European guidelines, no specific ethical ap-
roval was required for this observational study without
nvasive procedures.
phic cardiomyopathy (HCM) in a female pediatric patient. (A) The basal
) hypertrophy involving the intraventricular septum and the left posteriorertro
r (LVyears), the LV cavity has become enlarged and the walls have thinned in
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October 18, 2005:1543–50 Dilated-Hypokinetic Hypertrophic Cardiomyopathyefinitions. Dilated-hypokinetic evolution of HCM was
efined as development of hypokinetic and dilated LV, with
n end-diastolic cavity dimension measured by M-mode
chocardiography exceeding the reference upper 95% con-
dence interval (CI) for body surface area and an LVEF
50% (2,4,19). In patients who had already presented at
ur center with a dilated and hypokinetic LV, diagnosis of
CM always included previous echocardiographic docu-
entation of classic HCM. “Medical treatment at first
xamination” refers to pharmacologic treatment ongoing/
tarted at that time.
Other definitions were those commonly used. Sudden
ardiac death was defined as unexpected sudden collapse
ithin one hour of onset of symptoms occurring in patients
ho had previously experienced a relatively stable or un-
ventful clinical course. Heart failure-related death was
efined as death occurring in the context of cardiac decom-
ensation and progressive disease course one year or more
efore death.
tatistical analysis. The SPSS statistical package (SPSS
tatistical Software Inc., Chicago, Illinois) was used for all
nalysis. When not otherwise specified, data are expressed
s mean  1 SD, or as the number of patients (percentage).
revalence of dilated-hypokinetic HCM was calculated as
he ratio between patients with a diagnosis of dilated-
ypokinetic HCM at the first evaluation and the total
umber of study patients. Analysis of incidence was per-
ormed among those patients without dilated-hypokinetic
CM at first evaluation. Incidence was calculated as the
umber of patients who developed dilated-hypokinetic
CM during the follow-up period divided by the total
umber of person-years of observation accumulated in the
able 1. Baseline Characteristics of the Overall Population, Patie
CM at First Evaluation
Overall Population
(n  222)
ale gender 144 (65%)
amily history of HCM 65 (29%)
amily history of sudden death 47 (21%)
ge at diagnosis (yrs) 38  18
ge at first evaluation (yrs) 40  20
ediatric age (18 yrs) at first evaluation 42 (19%)
YHA functional class III to IV 22 (10%)
YHA functional class (mean) 1.5  0.7
yncope 21 (9%)
edical treatment at first examination 160 (72%)
ersistent atrial fibrillation 3 (1%)
eart failure episodes 12 (5%)
utflow obstruction 67 (30%)
aximum left ventricular wall thickness (mm) 19  6
nterventricular septal width (mm) 18  6
osterior wall thickness (mm) 13  4
eft ventricular end-diastolic diameter (mm) 43  11
nd-systolic left atrial diameter (mm) 43  10
eft ventricular ejection fraction (%) 67  8
pical HCM 8 (4%)
One patient with previous septal myectomy surgery was excluded from this analysis.
ith classic HCM at first evaluation.
HCM  hypertrophic cardiomyopathy; NA  not applicable (separation into subgrouptudy population; patients who underwent myotomy/
yectomy or percutaneous transluminal septal myocardial
blation were included in the analysis only up to the time of
he procedure. Differences between means were determined
sing the unpaired or paired Student t test as appropriate.
ifferences between proportions were determined using the
hi-square test. To assess the prognostic role of dilated-
ypokinetic HCM in terms of risk of cardiovascular death,
multivariate Cox proportional hazards model was fitted to
he data (20). The following variables were included: gen-
er, age at first evaluation, family history of sudden death,
ew York Heart Association (NYHA) functional class I to
I or III to IV, medical treatment at first evaluation,
onsustained ventricular tachycardia, LV outflow obstruc-
ion, maximum LV wall thickness, posterior wall thickness,
V end-diastolic diameter, end-systolic left atrial diameter,
nd (as a time-dependant covariate) dilated-hypokinetic
volution. Variables were selected in a stepwise forward
election manner with entry and retention set at a signifi-
ance level of 0.05. Probability of cardiovascular death-free
urvival was calculated using the Kaplan-Meier method, and
urvival curves were compared using the log-rank test.
ESULTS
tudy population. The mean age at first evaluation was 40
20 years; 144 (65%) patients were men, 42 (19%) were 18
ears old or younger. Baseline clinical and echocardiographic
haracteristics of the entire population as well as of the two
roups of patients with either dilated-hypokinetic or classic
CM at first evaluation are summarized in Table 1. During a
ean follow-up of 11  9 years, 29 (13%) patients devel-
ith Classic HCM, and Patients With Dilated-Hypokinetic
Dilated-Hypokinetic
HCM (n  11)*
Classic
HCM (n  210) p Value†
8 (73%) 135 (64%) 0.8
7 (64%) 58 (28%) 0.03
4 (36%) 43 (20%) 0.3
27  18 39  18 0.05
34  16 40  21 0.3
3 (27%) 37 (18%) 0.6
3 (27%) 19 (9%) 0.1
2.1  1.1 1.4  1.0 0.1
1 (9%) 19 (9%) 1
9 (82%) 151 (72%) 0.7
0 (0%) 3 (1%) 1
3 (27%) 9 (4%) 0.01
0 (0%) 68 (32%) 0.05
17  6 20  6 0.2
16  6 19  6 0.2
14  4 13  4 0.4
61  9 41  10 NA
49  8 42  10 0.02
32  10 66  8 NA
0 (0%) 8 (4%) 0.9
p values refer to comparison between patients with dilated-hypokinetic and patientsnts W
†Thes was based on these variables); NYHA  New York Heart Association.
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Dilated-Hypokinetic Hypertrophic Cardiomyopathy October 18, 2005:1543–50ped persistent atrial fibrillation, 65 (29%) had heart failure
pisodes, and 20 (9%) experienced syncope. Holter moni-
oring data were available for 190 (85%) patients; nonsus-
ained ventricular tachycardia was present in 64 of 190
atients (34%). A permanent pacemaker or cardioverter-
efibrillator was implanted in 10 (4%) and 11 (5%) patients,
espectively. During the follow-up period, 10 patients (4%)
nderwent heart transplantation and 50 (23%) died. The
ause of death was sudden in 20 patients (9%), heart
ailure-related in 13 patients (6%), stroke-related in 3
atients (1%) and due to noncardiac causes in 14 patients
6%).
revalence of dilated-hypokinetic evolution of HCM. The
iagnosis of dilated-hypokinetic HCM was made in 12
atients at the first evaluation. One of these patients, who
ad entered this phase after septal myectomy surgery, was
xcluded from the analysis. Therefore, 11 patients were
eemed to have dilated-hypokinetic HCM evolution at first
valuation, corresponding to a prevalence of 4.9%.
ncidence of dilated-hypokinetic evolution of HCM. Twelve
f the 211 patients with classic HCM at first evaluation
nderwent dilated-hypokinetic evolution (their changes in
V cavity dimension, LVEF, and maximum wall thickness
re individually represented in Fig. 2). Because all 12 of
hese patients belonged to the subgroup with regular
ollow-up data from our institutional program, an actuarial
ncidence curve was constructed (Fig. 3). The events (onset)
ere distributed rather evenly over almost the entire
ollow-up period (mean, 11  9 years; range, 4 months to
2 years). The overall incidence of development of dilated-
ypokinetic HCM was 5.3 per 1,000 patient-years. Of note,
restrictive LV filling pattern was present at echo-Doppler
valuation in 3 of 12 patients at the time of detection of
ilated-hypokinetic evolution.
haracterization of patients with dilated-hypokinetic
CM and prediction of onset. We first looked at the
linical/morphologic profile of patients with prevalent
ilated-hypokinetic HCM at baseline (n  11). A compar-
son between their clinical/morphologic characteristics and
hose of the rest of the population at first evaluation is
hown in Table 1.
To look for possible predictors of evolution, we then
nalyzed the baseline characteristics of patients who had
revalent/incident dilated-hypokinetic HCM (n  23).
able 2 shows a comparison of the baseline characteristics
f patients with dilated-hypokinetic HCM and patients
ho maintained classic HCM (it should be noted that for
hose patients with prevalent dilated-hypokinetic HCM,
easurements were retrieved from prior echocardiographic
ocumentation). At the univariate analysis, the two sub-
roups were similar regarding gender, symptoms, LV end-
iastolic volume, and LVEF. On morphologic grounds,
atients with dilated-hypokinetic HCM showed greater LV
arietal thickness at the posterior as well as interventricular
eptal level. They also more often had a family history of
CM or a family history of sudden death. They were oignificantly younger both at the original diagnosis of HCM
nd at first examination. Because of the small number of
atients with dilated-hypokinetic evolution, it was not
ossible to construct a valid multivariate model.
Of note, the 23 patients with prevalent/incident dilated-
ypokinetic evolution belonged to 18 distinct families.
mong these 18 nuclei, we could identify 3 pedigrees contain-
ng both sudden death in the context of nondilated HCM and
eath from heart failure attributable to end-stage evolution.
rognostic implications of dilated-hypokinetic HCM. Figure
shows actuarial cardiovascular death-free survival curves for
atients with prevalent or incident dilated-hypokinetic HCM
n  23) and the rest of the study population: patients with
ilated-hypokinetic evolution had a poorer cardiovascular
eath-free survival (p 0.04). In particular, of the 23 patients
ith dilated-hypokinetic evolution, 4 died of congestive heart
ailure and 3 died suddenly.
Cox proportional hazards regression analysis identified LV
all thickness (hazard ratio [HR]  1.07; 95% CI 1.01, to
.14; p  0.03) and LV end-diastolic diameter (HR  1.08;
5% CI, 1.04 to 1.11; p  0.0001) as independent predictors
igure 2. Changes in left ventricular (LV) maximal wall thickness (A), LV
nd-diastolic diameter (B), and LV ejection fraction (C) in the 12
ypertrophic cardiomyopathy (HCM) patients who underwent dilated-
ypokinetic evolution during the study period. SD  standard deviation.f cardiovascular death; dilated-hypokinetic evolution (consid-
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October 18, 2005:1543–50 Dilated-Hypokinetic Hypertrophic Cardiomyopathyred as a time-dependant covariate) did not independently
redict cardiovascular death-free survival (p  0.51).
Clinical events observed during follow-up among the
ubgroups of patients in whom dilated-hypokinetic HCM
id and did not develop during the study period are
ummarized in Table 3. Overall, patients in whom dilated-
ypokinetic HCM developed more often had persistent
trial fibrillation, episodes of heart failure, ventricular tachy-
ardia (on 24-h Holter monitoring), and heart transplanta-
ion. It should be noted, however, that this subgroup had a
onger follow-up (14  6 years vs. 10  7 years, p  0.05).
he first signs of LV dilation and hypokinesis in these 12
ncident patients became evident within 13  8 years
ranging from 5 to 33 years) after the diagnosis of HCM
mean age of patients, 42  17 years). The mean interval
rom echocardiographic appearance of LV dilation to de-
elopment of heart failure (NYHA functional class III to
V) was 3 2 years (range, 1 to 7 years). During follow-up,
igure 3. Actuarial incidence curve of dilated-hypokinetic evolution
mong 210 patients with classic hypertrophic cardiomyopathy at first
valuation.
Table 2. Baseline Clinical and Echocardiograp
Dilated-Hypokinetic HCM and Patients Who
Male gender
Family history of HCM
Family history of sudden death
Age at diagnosis (yrs)
Age at first evaluation (yrs)
Pediatric age (18 yrs) at first evaluation
NYHA functional class III to IV at first evaluation
NYHA functional class (mean)
Syncope at first evaluation
Medical treatment at first examination
Outflow obstruction
Maximum left ventricular wall thickness (mm)
Interventricular septal width (mm)
Posterior wall thickness (mm)
Left ventricular end-diastolic diameter (mm)
End-systolic left atrial diameter (mm)
Left ventricular ejection fraction (%)Abbreviations as in Table 1.wo (17%) patients died and five (45%) underwent heart
ransplantation. The mean time between identification of
ilated evolution and death or heart transplantation was 5
years and 5  4 years, respectively.
Five of 12 (42%) patients who experienced dilated-
ypokinetic evolution during follow-up were younger than
9 years of age at first evaluation; in this subgroup, dilated-
ypokinetic evolution occurred at 8 4 years (range, 5 to 16
ears) from HCM diagnosis. After LV dilation occurred,
eart failure symptoms developed earlier in these patients
ompared with adult patients (1  0.5 years vs. 5  3 years,
 0.05). Moreover, four of five (80%) pediatric patients
nderwent heart transplantation (at 5  4 years from
ppearance of dilation) and one (8%) died of heart failure (at
years from dilation).
igure 4. Kaplan-Meier estimates of cardiovascular death-free survival of
atients with and without prevalent/incident dilated-hypokinetic hypertro-
hic cardiomyopathy (HCM).
eatures of Patients With Prevalent/Incident
ntained Classic HCM
lated-Hypokinetic
HCM (n  23)
Classic
HCM (n  198) p Value
17 (74%) 126 (64%) 0.5
14 (61%) 51 (26%) 0.002
10 (43%) 37 (19%) 0.01
28  15 39  18 0.03
32  14 41  21 0.04
9 (39%) 34 (17%) 0.02
0 (0%) 19 (9%) 0.5
1.5  0.6 1.4  0.7 0.8
2 (9%) 18 (9%) 0.99
17 (74%) 141 (71%) 1
4 (17%) 67 (30%) 0.2
24  3 20  6 0.001
23  3 19  6 0.004
15  3 13  4 0.006
43  4 41  9 0.7
45  7 42  10 0.1
66  4 66  8 1hic F
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Dilated-Hypokinetic Hypertrophic Cardiomyopathy October 18, 2005:1543–50ISCUSSION
ilated-hypokinetic evolution of HCM is responsible for
evere heart-failure symptoms and is the single most fre-
uent indication for heart transplantation among HCM
atients (3,13,14). This study of a large population of HCM
atients routinely followed up at a single cardiology center
rovides valuable data on the incidence of dilated-
ypokinetic evolution among both children and adults, as
ell as on possible clinical and echocardiographic risk
actors for development of this peculiar disease pathway.
revalence and incidence of dilated-hypokinetic HCM.
ince the 1980s, dilated-hypokinetic (end-stage) evolution
f HCM has become an established clinical entity, and its
ecognition is clearly based on the presence of cavity size
nlargement and LV systolic dysfunction, commonly ac-
ompanied by ventricular wall thinning (1,2,4–7,9). Our
efinition of dilated-hypokinetic HCM was based on the
imultaneous presence of LV cavity dilation and reduced
VEF, not necessarily associated with thinned LV walls. It
s noteworthy, however, that LV wall thinning was docu-
ented during the study period in all but one patient (Fig.
). Outside of heart transplantation centers, the prevalence
f dilated-hypokinetic HCM has generally been reported to
ange from about 5% to 15% (4). However, these figures
ere produced without excluding patients who had previ-
usly undergone myotomy-myectomy, and are likely to give
ise to a somewhat distorted picture [because myectomy can
lter LV end-diastolic diameter as routinely measured by
-mode according to the recommendations of the Amer-
can Society of Echocardiography, whereas percutaneous
eptal myocardial ablation can induce LV remodeling with
ncreased volumes (21)]. After exclusion of such cases, the
ecorded prevalence of dilated-hypokinetic HCM in our
enter was 4.9%.
To our knowledge, this is the first time that the incidence
f dilated-hypokinetic evolution has been studied in a large
opulation of HCM patients not submitted to surgical/
Table 3. Clinical Events Observed in Patients
During Follow-Up and in Patients Who Main
D
Persistent atrial fibrillation
Heart failure episodes
Syncope
Sustained/nonsustained ventricular tachycardia
on Holter electrocardiogram
Pacemaker
Implanted cardioverter-defibrillator
Cardiovascular death
Sudden death
Heart failure–related death
Stroke-related death
Noncardiovascular death
Heart transplantation
HCM  hypertrophic cardiomyopathy.blative myectomy. The overall incidence recorded was 5.3 eer 1,000 patient-years, with a rather even distribution of
nset over almost the entire follow-up period (Fig. 3).
rediction of onset of dilated-hypokinetic evolution. In-
reased posterior wall thickness was the most peculiar
orphologic trait in patients with (prevalent/incident)
ilated-hypokinetic HCM (Table 2). The pathogenetic
ignificance of this morphologic peculiarity is unclear. One
ttractive hypothesis is that this phenotypic peculiarity
ight constitute a marker of a distinct genotype (unfortu-
ately, our study did not contemplate systematic genotyp-
ng). Alternatively, it is conceivable that a widespread
istribution of LV hypertrophy might exacerbate myocar-
ial ischemia, a very common phenomenon in HCM, and
ventually lead to global LV dysfunction. The HCM
haracterized on echocardiography by marked thickening of
he posterior LV free wall has been previously described to
e associated with early (before the age of 40 years) onset of
evere symptoms, such as dyspnea, syncope, chest pain, and
alpitations (22). However, no relationship between this
eculiar morphologic feature of HCM and dilated-
ypokinetic evolution has been previously reported.
atural history and prognostic implications of dilated-
ypokinetic evolution. Despite the younger age at first
valuation of patients who developed dilated-hypokinetic
CM during follow-up, the interval from diagnosis to LV
nlargement was rather long. However, once the dilation was
stablished, the evolution toward heart failure and hence
ransplantation or death was rapid. The vast majority of our
atients with dilated-hypokinetic evolution of HCM had
evere symptoms (NYHA functional class IV) and were
efractory to medical treatment in spite of a depression of
VEF that might be considered only moderate in comparison
ith heart transplantation candidates with idiopathic dilated
ardiomyopathy (Fig. 2). A combination of both diastolic and
ystolic dysfunction could explain this apparent discrepancy.
athogenesis of dilated-hypokinetic evolution in HCM. The
ost likely pathogenetic mechanisms of dilated-hypokinetic
Underwent Dilated-Hypokinetic Evolution
d Classic HCM
d-Hypokinetic
tion (n  12)
Classic
HCM (n  198) p Value
5 (42%) 22 (11%) 0.009
10 (83%) 48 (24%) 0.0001
2 (17%) 19 (9%) 0.8
/12 (75%) 49/175 (28%) 0.002
1 (8%) 8 (4%) 1
2 (17%) 8 (4%) 0.2
2 (17%) 26 (13%) 0.1
1 (8%) 17 (9%) 1
1 (8%) 9 (4%) 1
0 (0%) 3 (1%) 1
0 (0%) 14 (7%) 0.7
5 (42%) 1 (0.5%) 0.0001Who
taine
ilate
Evolu
9volution of HCM have been widely discussed in the
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October 18, 2005:1543–50 Dilated-Hypokinetic Hypertrophic Cardiomyopathyiterature. Based on histology, importance has been given to
mall-vessel disease, myocardial disarray, or replacement
brosis (10,11,23–26). Recently, gadolinium-enhanced car-
iac magnetic resonance has provided in vivo confirmation
hat interstitial and replacement fibrosis is the most frequent
yocardial substrate of this evolutionary pathway (11). The
resent study was not designed to clarify the pathogenetic
echanism of dilated-hypokinetic HCM. However, analy-
is of the clinical and morphologic data regarding our
revalent and incident cases can provide some hints regard-
ng the likely pathogenesis. In our two analyses (Tables 1
nd 2), dilated-hypokinetic evolution was most often al-
eady present in the third decade of life, and about one-third
f the cases were actually pediatric; furthermore, age at
iagnosis of HCM seemed to be lower in patients with
ilated-hypokinetic evolution compared with the rest of the
opulation. These observations make a strict aging-related
echanism seem rather unlikely. On the other hand, they fit
uite well with the hypothesis that dilated-hypokinetic
CM often has a genetic basis (27–29). In some families,
volution to the dilated-hypokinetic evolution of HCM
eems to occur with a particularly high frequency. A number
f mutations in gene encoding proteins of the cardiac
arcomere have been reported in HCM patients in the
ilated-hypokinetic evolution. It is unlikely that the
ropensity to develop this clinical course is exclusively
ttributable to any specific HCM-causing mutant gene.
nterestingly, Seidman et al. (12) recently showed that
utations in the same gene (heavy-chain beta-myosin)
an cause either hypertrophic or dilated cardiomyopathy.
he development of LV wall thinning and systolic
ysfunction probably represents a more complex phe-
omenon influenced by modifier genes as well as envi-
onmental factors.
onsiderations regarding the pediatric population. Our
ata indicate that HCM patients diagnosed at a pediatric
ge are a high-risk subgroup regarding not only sudden
eath but also congestive heart failure. It is known that the
orphologic basis for congestive heart failure in newborns
ith HCM is massive biventricular hypertrophy, frequently
ssociated with right ventricular and/or LV obstruction.
ur data set shows that dilated-hypokinetic evolution is
nother pathophysiologic substrate apparently affecting older
hildren and adolescents. In the clinical arena, this peculiar
isease pathway of classic HCM must be distinguished from
ther genetically determined entities that share the same
henotype of symmetrical LV hypertrophy and LV systolic
ysfunction, and especially cardiomyopathies associated with
itochondrial disease. The latter, however, are generally char-
cterized by multiorgan involvement, which should provide a
aluable clue for a differential diagnosis.
LINICAL IMPLICATIONS AND CONCLUSIONS
he evolution toward a dilated-hypokinetic phase is rare but
ot exceptional in HCM, particularly among young patientsith hypertrophy not confined to the interventricular sep-
um, but also involving the posterior wall. Recognition of
his risk profile in individual patients should encourage close
ollow-up, aimed at timely detection and treatment of
ongestive heart failure. We think that the option of heart
ransplantation deserves consideration (and discussion with
he patient) on the first appearance of heart failure symp-
oms, even if these occur before overt deterioration of
ystolic function.
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